	Office of Researce Human Su		SOP #: Revision #: Page #:	ORI (HS)-8.01 1.0 Page 1 of 9
Approved By: ORI Executive Director	*Sgnature on file	Date:	Date First Effe 03/ 13/ 2019	ctive:
Approved by: Biomedical Chair	*Sgnature on file	Date:		
Approved by: Social Behavioral Chair	*Sgnature on file	Date	Revision Date:	

UNLV Office of Research Integrity - Human Subjects and Institutional Review Board			
Standard Operating Procedures			
SOP #:ORI (HS)- 8.01	TITLE: Drugs, Biologics and Dietary	Page 2 of 9	
Revision #:	Supplements Regulations	-	

UNLV Office of Research Integrity - Human Subjects and Institutional Review Board Standard Operating Procedures OP #:ORI(HS)- 8.01 TITLE: Drugs, Biologics and Dietary evision #: Supplements Regulations Page 3 of 9

SOP #:ORI(HS)- 8.01 Revision #:

UNLV Office of Research Integrity - Human Subjects and Institutional Review Board			
Standard Operating Procedures			
SOP #:ORI (HS)- 8.01	TITLE: Drugs, Biologics and Dietary	Page 4 of 9	
Revision #:	Supplements Regulations	-	

Th

UNLV Office of Research Integrity - Human Subjects and Institutional Review Board			
Standard Operating Procedures			
SOP #:ORI (HS)- 8.01	TITLE: Drugs, Biologics and Dietary	Page 5 of 9	
Revision #:	Supplements Regulations		

UNLV Office of Research Integrity - Human Subjects and Institutional Review Board			
Standard Operating Procedures			
SOP #:ORI (HS)- 8.01	TITLE: Drugs, Biologics and Dietary	Page 9 of 9	
Revision #:	Supplements Regulations		

5. References

21 CFR 50, 56, and 312.

International Conference on Harmonization (ICH) guidance for industry, E6 Good Clinical Practice: Consolidated Guidance (Good Clinical Practice Guidance).